Is Innoviva, Inc. (INVA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 16.3% / 30% | 34.4% / 30% | 5.7% / 30% | 5.13% / 5% | ✗ NOT HALAL |
| DJIM | 16.3% / 33% | 34.4% / 33% | 5.7% / 33% | 5.13% / 5% | ✗ NOT HALAL |
| MSCI | 16.5% / 33% | 34.7% / 33% | 5.7% / 33% | 5.13% / 5% | ✗ NOT HALAL |
| S&P | 16.3% / 33% | 34.4% / 33% | 5.7% / 33% | 5.13% / 5% | ✗ NOT HALAL |
| FTSE | 16.5% / 33% | 34.7% / 33% | 5.7% / 50% | 5.13% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 74.9% | |
| Operating Margin | 34.7% | |
| Net Margin | 65.9% | |
| Return on Equity (ROE) | 29.1% | |
| Return on Assets (ROA) | 7.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $197M |
| Free Cash Flow | $186M |
| Total Debt | $269M |
| Debt-to-Equity | 28.2 |
| Current Ratio | 14.6 |
| Total Assets | $1.6B |
Price & Trading
| Last Close | $22.66 |
| 50-Day MA | $21.82 |
| 200-Day MA | $20.19 |
| Avg Volume | 745K |
| Beta | 0.4 |
|
52-Week Range
$16.52
| |
About Innoviva, Inc. (INVA)
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Innoviva, Inc. (INVA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Innoviva, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Innoviva, Inc.'s debt ratio?
Innoviva, Inc.'s debt ratio is 16.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.5%.
What are Innoviva, Inc.'s key financial metrics?
Innoviva, Inc. has a market capitalization of $1.7B, trailing P/E ratio of 6.9, and revenue of $411M. The company maintains a gross margin of 74.9% and a net margin of 65.9%. Return on equity stands at 29.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.